An investigation for investors in NASDAQ:NVLS shares was announced over possible securities laws violations by Nivalis Therapeutics Inc and certain of its directors and officers.
Investors who purchased shares of Nivalis Therapeutics Inc (NASDAQ:NVLS), have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether a series of statements by Nivalis Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
On November 28, 2016, Nivalis Therapeutics Inc announced that its Phase 2 Trial of Cavosonstat failed to meet its primary endpoint of demonstrating a benefit in the absolute change in percent-predicted FEV1 (lung function) or in sweat chloride reduction at 12 weeks, in comparison to placebo.
Shares of Nivalis Therapeutics Inc (NASDAQ:NVLS) declined on December 12, 2016, to as low as $2.14 per share.
Those who purchased NASDAQ:NVLS shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego